The new report, “Pharmaceutical Processing and Packaging Equipment Market: Size, Share, Forecast, and Trends Analysis by Formulation, Secondary Packaging, and End-of-Line Packaging – Global Forecast to 2031,” is now available on ResearchAndMarkets.com. The global pharmaceutical processing and packaging equipment market…
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that the European Commission (EC) has granted approval for Ordspono™ (odronextamab) to treat adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) who have undergone…
Bristol Myers Squibb (NYSE: BMY) has announced that it will present research findings from its comprehensive cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, scheduled for August 30 – September 2, 2024, in London, England. The presentations will…
In 2017, Maria Morais began experiencing severe abdominal pain, which led to gall bladder surgery. However, when the procedure failed to alleviate her discomfort, follow-up tests revealed alarmingly high liver enzyme levels. As a registered nurse, Maria recognized that something…
Eisai Co., Ltd. (Tokyo, CEO: Haruo Naito) and Biogen Inc. (Cambridge, Massachusetts, CEO: Christopher A. Viehbacher) have announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain has granted Marketing Authorization for their humanized amyloid-beta (Aβ) monoclonal…
Moderna, Inc. (NASDAQ) has announced that the European Commission (EC) has granted marketing authorization for mRESVIA® (mRNA-1345), an mRNA vaccine designed to protect adults aged 60 and older from lower respiratory tract disease caused by RSV (respiratory syncytial virus). This…
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has announced key leadership changes in its research and development and business development teams. Effective September 30, Greg Friberg, M.D., will join the company as Executive Vice President and Chief Research & Development Officer, succeeding…
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced the top-line results from a Phase 3 open-label, single-arm trial conducted in Japan. The study assessed the safety and efficacy of their cannabidiol oral solution, marketed globally as Epidiolex®/Epidyolex®, as an adjunctive treatment…
Incyte (Nasdaq: INCY) today reported positive results from the pivotal Phase 3 inMIND study, which evaluated the efficacy and safety of tafasitamab (Monjuvi®), a humanized Fc-modified cytolytic CD19-targeted monoclonal antibody, in combination with lenalidomide and rituximab, versus placebo combined with…
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been conditionally approved in China for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have undergone two or more prior treatments. The approval by the…
Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, has announced its unaudited financial results and notable corporate developments for the second quarter of 2024. CEO Statement Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech, commented, “The…
Vertex Announces Reimbursement Agreement with NHS England for CASGEVY™ Vertex has announced a new reimbursement agreement with NHS England, effective immediately, allowing eligible patients with transfusion-dependent beta thalassemia (TDT) to access CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy. This agreement…